Immunic, Inc. (IMUX)

NASDAQ: IMUX · IEX Real-Time Price · USD
5.00
+0.08 (1.63%)
Aug 12, 2022 10:57 AM EDT - Market open
1.63%
Market Cap 152.82M
Revenue (ttm) n/a
Net Income (ttm) -83.19M
Shares Out 30.56M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,795
Open 5.02
Previous Close 4.92
Day's Range 4.93 - 5.09
52-Week Range 2.52 - 14.50
Beta 2.00
Analysts Buy
Price Target 30.02 (+500.4%)
Earnings Date Aug 4, 2022

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR"t; and IMU-856 for the restoration of the intes... [Read more...]

Industry Biotechnology
CEO Daniel Vitt
Employees 60
Stock Exchange NASDAQ
Ticker Symbol IMUX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is 30.02, which is an increase of 500.40% from the latest price.

Price Target
$30.02
(500.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter – – Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Trial of IMU-85...

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

NEW YORK , Aug. 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK , July 28, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selectiv...

Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade

Immunic (IMUX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

– Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Board After Six Year Tenure – NEW YORK , July 6, 2022 /PRNewswire/ -- Immunic , Inc...

Immunic to Participate in Industry and Scientific Conferences in July

NEW YORK , June 28, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chroni...

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting ...

NEW YORK , June 15, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chroni...

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic...

Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails

Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.

Why is Immunic (IMUX) Stock Plunging 40% Today?

Immunic (IMUX) stock is falling hard on Thursday after the company released poor results from a recent Phase 2 clinical trial. The post Why is Immunic (IMUX) Stock Plunging 40% Today?

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to...

– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids – – In UC Populati...

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – – Part C Portion of Phase 1 Trial of IMU-935 in Psoriasis Patients Ong...

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

– First Time Patients Will be Treated with the Company's Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium  – NEW YORK ,...

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ora...

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

NEW YORK , April 25, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chron...

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

NEW YORK , March 16, 2022 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chron...

Immunic, Inc. to Participate in Investor and Scientific Conferences in March

NEW YORK, March 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

NEW YORK, Feb. 24, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colit...

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

Immunic, Inc. to Participate in Investor and Scientific Conferences in February

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935...

NEW YORK, Feb. 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic i...

Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?

Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.

Can Immunic (IMUX) Climb 357% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 357.4% upside potential for Immunic (IMUX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Tr...

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...